Eli Lilly Lowers Zepbound Price, Following Novo Nordisk

Eli Lilly reduces Zepbound price to $299 per month, following Novo Nordisks price cuts for Ozempic and Wegovy. This move aims to provide more affordable options for patients, as both drugs target the GLP-one hormone for appetite control. The price reduction is part of an agreement with the Trump administration to further lower costs next year, making these drugs accessible to Medicare and Medicaid beneficiaries for weight loss treatment.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.